Mahnoor Ali

Mahnoor Ali

Auto-generated profile, based on publicly available information

Mahnoor Ali

Fatima Jinnah Medical University , Lahore

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2026 in Rheumatology
Verified
Journal Article
Closed access
RFRija Fatima
Rija Fatima
SISaira Iqbal
Saira Iqbal
FAFahad Amin
Fahad Amin
KMKhubaib Tariq Mansoor
Khubaib Tariq Mansoor
ZHZohaib Hassan
Zohaib Hassan
MAMahnoor Ali
Mahnoor Ali
Objectives: Takayasu arteritis (TAK) is a rare chronic granulomatous vasculitis affecting large arteries, causing recurrent disease despite standard treatment. This systematic review and meta-analysis aimed to evaluate efficacy and safety of Janus kinase inhibitors in patients with refractory Takayasu arteritis. Methods: We searched five major databases from inception through July 16, 2026, for observational cohorts, non-randomized interventional studies, and case series including ≥5 patients. Eligible studies enrolled adults with refractory TAK treated with JAK inhibitors. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane ROBINS-I and Joanna Briggs Institute tools. The protocol was registered in PROSPERO (CRD420261469541). GRADE was used to assess certainty of primary efficacy outcomes. Results: Eleven studies comprising 185 patients were included. The pooled clinical remission rate was 64% (95% CI, 55%–72%; I²=0%), while complete and partial remission rates were 65% (95% CI, 55%–74%) and 8% (95% CI, 4%–17%), respectively. Pooled rates of no response and relapse were 24% and 14%, respectively. Imaging improvement or stabilization was observed in 44% of patients, while glucocorticoid-sparing effects occurred in 56%. Adverse events occurred in 10% of patients, and 7% discontinued treatment because of adverse events. GRADE certainty was very low for all assessed outcomes. Conclusion: JAK inhibitors demonstrate promising clinical efficacy and a potentially manageable safety profile in refractory TAK. However, the available evidence is predominantly observational and therefore subject to confounding and other sources of bias. High-quality prospective and randomized studies are needed to establish their efficacy, comparative effectiveness, and long-term safety.